Shi Peiying, Xie Yunjiao, Xie Rongfang, Lin Zuan, Yao Hong, Wu Shuang
Department of Traditional Chinese Medicine Resource and Bee Products, College of Animal Science (College of Bee Science), Fujian Agriculture and Forestry University, Fuzhou, China.
College of Horticulture, FAFU-UCR Joint Center and Fujian Provincial Key Laboratory of Haixia Applied Plant Systems Biology, Fujian Agriculture and Forestry University, Fuzhou, China.
Front Pharmacol. 2020 Aug 14;11:1295. doi: 10.3389/fphar.2020.01295. eCollection 2020.
In this paper, the integrated pharmacokinetics (PK) of an extract preparation (ASEP, named as Ciwujia injection in clinic in China) was explored by combining with multi-component PK in rats, virtual screening, systems pharmacology and molecular docking. Firstly, the ingredients in ASEP with high contents and detectable property in rat plasma were selected. Next, the PK study of the resulted ingredients was performed in rats (1.76 ml/kg and 3.52 ml/kg of 5 times concentrated ASEP, single i.v.). Meanwhile, the drug targets for the ingredients screened out were predicted by using a target fishing online server, PharmMapper (http://www.lilab-ecust.cn/pharmmapper/) with a fit filtration threshold of z'-score >0. Next, the network pharmacology, molecular docking, diseases ontology (DO) analysis, and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed respectively for the predicted targets. Finally, the supporting evidences were obtained to characterize the PK markers and carry out the integrated PK study with "plasma-drug concentration sum" or "plasma-drug AUC weighted" methods. As a result, 6 ingredients, involving 5-caffeoylquinic acid (5-CQA), 3-CQA, 4-CQA, protocatechuic acid, eleutheroside B, and gentiopicroside were selected, and their PK profiles were elucidated. The 6 ingredients were highly related to arteriosclerotic cardiovascular disease and atherosclerosis and could mainly interact with similar targets, e.g., GSK3B, PDPK1, PLAU, etc., or pathways, e.g., Insulin, VEGF, FoxO, etc, providing the basis for integrating plasma drug concentration. Ultimately, the 6 ingredients were considered as PK markers and the whole process of ASEP were characterized. Our study would enhance understanding of the therapeutic effects and mechanisms of ASEP against cardiovascular diseases, and provided useful insights for future integrated PK study on anti-cardiovascular diseases TCM injections.
在本文中,通过结合大鼠体内多组分药代动力学、虚拟筛选、系统药理学和分子对接,对一种提取物制剂(ASEP,在中国临床中名为刺五加注射液)的整合药代动力学(PK)进行了研究。首先,选取了在大鼠血浆中含量高且可检测的ASEP中的成分。接下来,对所得成分进行大鼠体内PK研究(5倍浓缩的ASEP,静脉注射,剂量分别为1.76 ml/kg和3.52 ml/kg)。同时,使用在线靶标筛选服务器PharmMapper(http://www.lilab-ecust.cn/pharmmapper/),以拟合过滤阈值z'-score >0预测筛选出的成分所对应的药物靶点。然后,分别对预测出的靶点进行网络药理学、分子对接、疾病本体(DO)分析以及京都基因与基因组百科全书(KEGG)通路富集分析。最后,获得支持证据以表征PK标志物,并采用“血浆药物浓度总和”或“血浆药物AUC加权”方法进行整合PK研究。结果,选取了6种成分,包括5-咖啡酰奎宁酸(5-CQA)、3-CQA、4-CQA、原儿茶酸、刺五加苷B和龙胆苦苷,并阐明了它们的PK特征。这6种成分与动脉粥样硬化性心血管疾病和动脉粥样硬化高度相关,且主要与相似的靶点相互作用,如GSK3B、PDPK1、PLAU等,或与相似的通路相互作用,如胰岛素、VEGF、FoxO等,为整合血浆药物浓度提供了依据。最终,这6种成分被视为PK标志物,并对ASEP的全过程进行了表征。我们的研究将增进对ASEP治疗心血管疾病的疗效和机制的理解,并为未来抗心血管疾病中药注射剂的整合PK研究提供有益的见解。